

27 October 2026

Argent BioPharma Executes Exclusive Global Licence for Non-Core Cannabis Genetics

Highlights

- Argent BioPharma enters into a 10-year exclusive worldwide licensing agreement with Thai Phytomed International Co., Ltd. ("TPI") covering four proprietary cannabis genotypes
- Argent retains ownership of the underlying genetics and associated intellectual property
- TPI receives exclusive global commercialisation rights covering cultivation, processing, extraction, manufacturing and commercial sale of products derived from the licensed genetics
- Argent to receive a 15% royalty based on profits generated from commercialisation of the licensed genetics, including qualifying sublicensing activities
- TPI responsible for funding commercialisation and obtaining the regulatory and operational approvals required in each market
- Transaction supports Argent BioPharma's strategy of monetising non-core legacy assets while maintaining its internal focus on pharmaceutical development, immune modulation and anti-inflammatory therapeutics

Argent BioPharma Ltd. (ASX: RGT) ("**Argent BioPharma**", "**Argent**" or the "**Company**") is pleased to announce that it has entered into a 10-year exclusive worldwide licensing agreement with Thai Phytomed International Co., Ltd. ("TPI") for the commercial development of four cannabis genotypes owned within the Argent BioPharma Group.

The transaction forms part of Argent BioPharma's continuing strategy to extract value from its historical cannabis asset base through capital-efficient licensing arrangements, while focusing the Company's internal scientific and financial resources on its pharmaceutical, immune-modulation and anti-inflammatory development portfolio.


Under the agreement, TPI receives exclusive worldwide rights to commercially cultivate, propagate, process, extract, manufacture, market, distribute, sell, import and export the licensed genetics and products derived from them, including flower, extracts and cannabinoid active pharmaceutical ingredients, subject to applicable regulatory requirements.

The licence has an initial term of 10 years and may be renewed for a further 10 years on the same terms by written confirmation of both parties.

Four Proprietary Genetics Included

The agreement covers four cannabis genotypes developed and maintained within the Argent BioPharma Group:

- MXC-THC-10/3
- MXC-THC-81/5
- MXC-THC-40/3
- MXC-THC-40/2



The underlying genetics and associated intellectual property remain owned by Argent BioPharma (UK) Ltd, formerly MGC Pharma (UK) Ltd, which is wholly owned by Argent BioPharma Limited.

Importantly, the licensing arrangement does not constitute a sale or transfer of ownership of the genetics or associated intellectual property.

Argent retains the right to utilise the licensed genetics for internal pharmaceutical research and development, while TPI receives the exclusive commercial rights within the agreed licensed scope for the duration of the agreement.

The agreement does not include rights to CannEpil®, CimetrA®, the Company's other pharmaceutical products, clinical dossiers, formulations or proprietary drug delivery technologies.

Commercial Structure

Under the agreement, Argent BioPharma will receive a royalty equal to 15% of profits generated from the commercialisation of the licensed genetics.

Royalty calculations will be undertaken quarterly and will apply to commercialisation conducted directly by TPI, through TPI-controlled operating entities and through permitted sublicensing arrangements.

Argent BioPharma may terminate the licence if no commercial sale of licensed products has been made within 24 months after delivery of the licensed genetic material.

TPI will be responsible for funding the commercial development of the licensed genetics and for obtaining and maintaining the cultivation, handling, manufacturing, quality, product, import and export approvals required within each jurisdiction in which it operates.

The agreement also permits TPI to establish sublicensing arrangements to support international commercialisation, subject to the commercial, reporting, intellectual property and compliance protections contained within the licence.

Strategic Rationale


The transaction represents another step in Argent BioPharma's transition toward a more focused pharmaceutical and intellectual property business.

Following the global licensing of CannEpil®, the Company has continued to review its historical asset portfolio to identify opportunities where non-core assets can be commercialised by specialist external partners while Argent retains ownership and long-term economic participation.

The Board believes the licensing of these genetics provides a capital-efficient opportunity to generate potential future royalty revenues from assets that are no longer central to Argent BioPharma's internal development strategy.

For personal use only





At the same time, the structure preserves the underlying intellectual property within the Argent BioPharma Group and maintains the Company's ability to utilise the genetics for internal pharmaceutical research and development.

Roby Zomer, Executive Chairman, commented:

"This agreement is another example of how we intend to unlock value from Argent BioPharma's historical asset base while continuing to simplify and sharpen the strategic focus of the Company."

These genetics represent intellectual property developed within the Group over many years. Rather than continuing to deploy Argent's capital and operational resources toward their commercial development, we believe the appropriate strategy is to place them with a dedicated commercial partner while retaining ownership of the underlying assets and participating in their future success through royalties.

Importantly, the transaction does not include CannEpil®, Cimetra® or our pharmaceutical delivery technologies, and we retain the ability to utilise the genetics for internal pharmaceutical research.

This structure allows Argent to maintain economic exposure to these legacy assets without diverting resources from our core direction as we increasingly focus the Company on immune modulation, anti-inflammatory therapeutics and proprietary pharmaceutical intellectual property."

Willy Kruh, Executive Chairman, Thai Phytomed International, commented:

"Thai Phytomed International is pleased to be adding these well researched, high value genetics to our library of available, high-quality Thai-grown Medical Cannabis Flower and other products being supplied to global markets. The high THC (38-42% THC) and Balanced Genetics (12-14 % THC / 12-14% CBD) both represent existing needs in the market which Thai Phytomed International will be positioned to fulfill via this agreement with Argent. We look forward to a long and profitable relationship together as the Global Cannabinoid market further expands and develops."

—Ends—

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma

Roby Zomer
Executive Chairman

+61 8 6555 2950

info@argentbiopharma.com

Argent BioPharma


Rowan Harland
Company Secretary

+61 8 6555 2950

info@argentbiopharma.com

For personal use only





About Argent BioPharma

Argent BioPharma Ltd. (ASX: RGT) is a revenue-generating specialty biopharmaceutical company focused on building a differentiated immune-modulation intellectual property platform through the development, commercialisation and strategic licensing of innovative therapeutics.

The Company's portfolio is anchored by CimetrA®, its lead immune-modulation platform targeting inflammatory and autoimmune diseases, supported by next-generation NanoBodies and peptide technologies, proprietary drug delivery systems and pharmaceutical manufacturing capabilities.

Argent BioPharma's strategy combines intellectual property ownership, focused pharmaceutical development, manufacturing and strategic licensing, allowing the Company to monetise mature and non-core assets while concentrating internal resources on the development of its core immune-modulation portfolio.

About Thai Phytomed International Co.

Thai Phytomed International ("TPI") is a Thailand-based cannabinoid supply and commercialisation company focused on connecting the Thai cannabis industry with regulated international medical markets. Through its network of cultivation partners, TPI facilitates the production and export of cannabis products tailored to international buyers' specifications, while developing supply chains and regulatory market access. The Company combines expertise in international cannabis operations, strategic partnerships and intellectual property commercialisation, supported by an experienced leadership team with backgrounds in pharmaceutical development, corporate governance and regulated cannabis markets across Europe, North America and Thailand.

For personal use only

